Table 4.

Change in hemoglobin levels (g/dL) in response to mitapivat treatment

MeasurementNMeanSD25th percentileMedian75th percentile
Baseline 16 0.00 0.00 0.00 0.0 0.00 
5 mg BID 16 0.34 0.70 −0.12 0.3 0.80 
20 mg BID 16 0.76 0.96 −0.10 0.7 1.30 
50 mg BID 16 1.19 0.95 0.57 1.1 1.65 
100 mg BID 0.87 1.12 0.40 0.8 0.90 
End of taper 15 0.29 0.82 −0.20 0.3 0.55 
End of study 15 0.40 0.69 0.05 0.6 0.90 
MeasurementNMeanSD25th percentileMedian75th percentile
Baseline 16 0.00 0.00 0.00 0.0 0.00 
5 mg BID 16 0.34 0.70 −0.12 0.3 0.80 
20 mg BID 16 0.76 0.96 −0.10 0.7 1.30 
50 mg BID 16 1.19 0.95 0.57 1.1 1.65 
100 mg BID 0.87 1.12 0.40 0.8 0.90 
End of taper 15 0.29 0.82 −0.20 0.3 0.55 
End of study 15 0.40 0.69 0.05 0.6 0.90 
Close Modal

or Create an Account

Close Modal
Close Modal